| 1,042 | 23 | 59 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：系统评价中医药对肿瘤蒽环类化疗导致心脏毒性保护作用的疗效，为临床提供指导。方法：计算机检索中国知网数据库（CNKI）、中国生物医学文献检索（SinoMed）、万方数据知识服务系统（WanFang Data）、维普全文数据库（VIP）、PubMed、MedLine、cochrane library，搜集有关中医药治疗肿瘤蒽环类化疗导致心脏毒性的随机对照试验（RCT），由2位研究人员筛查从建库至2020年12月1日的文献，提取所需指标，并纳入RevMan5.4分析。纳入的RCT依据Cochrane手册进行偏倚风险评估。结果：纳入37项RCT，共计2 844名患者。Meta分析结果显示，治疗组与对照组相比较，中医药治疗能减轻蒽环类化疗药降低左心室射血分数[WMD=6.44,95%CI(0.38～12.50),P=0.04]，增大左心室收缩末期内径[WMD=-0.47,95%CI（-0.60～-0.34）,P<0.000 01]和左心室舒张末期内径[WMD=-0.59,95%CI（-0.74～-0.44）,P<0.000 01]的作用，并降低蒽环类药物升高肌钙蛋白I[WMD=-0.19,95%CI（-0.23～-0.16）,P<0.000 01]、肌钙蛋白T[WMD=-0.02,95%CI（-0.03～-0.01）,P<0.000 01]和脑钠肽[WMD=-32.21,95%CI（-58.21～-6.22）,P=0.02]等心肌损伤物的作用，差异具有统计学意义。结论：目前现有证据可以证明中医药在对肿瘤蒽环类化疗导致心脏毒性方面具有保护作用，维持左室射血分数和心室直径，控制心肌损伤标志物水平，减轻心脏损伤。
Abstract：Objective:To systematically evaluate the therapeutic effect of TCM on cardiotoxicity induced by anthracycline chemotherapy to provide clinical guidance. Methods:China hownet database(CNKI),Chinese biomedical literature retrieval(SinoMed),ten thousand Data knowledge service system(WanFang Data),VIP full-text database(VIP),PubMed,MedLine and the cochrane library were searched from inception to 1 st,December,2020. Relevant combined TCM and Western medicine on cardiotoxicity randomized controlled trials(RCT)were collected. The risk of bias in included RCTs were evaluated according to the Cochrane Handbook. The required indicators were extracted and included in RevMan5.4 analysis.Results:A total of 2 844 patients were included in 37 RCTS. The results of meta-analysis showed that compared with the control group,TCM treatment group could alleviate the effect of anthracycline on ventricular ejection function,reduce the effect of anthracycline chemotherapy drugs in lowering left ventricular ejection fraction(WMD=6.44,95%CI 0.38 to 12.50,P=0.04),reduce the effect of anthracycline chemotherapy in increasing left ventricular end diastolic diameter(WMD=-0.59,95%CI-0.74 to-0.44,P<0.000 01),reduce the effect of anthracycline chemotherapy drugs in increasing left ventricular end systolic diameter(WMD=-0.47,95%CI-0.60 to-0.34,P<0.000 01),and reduce the effect of anthracyclines on troponin I(WMD=-0.19,95%CI-0.23 to-0.16,P<0.000 01)、troponin T(WMD=-0.02,95%CI-0.03 to-0.01,P<0.000 01)and brain natriuretic peptide(WMD=-32.21,95%CI-58.21 to-6.22,P=0.02).Conclusion:The existing evidence can prove that TCM has a protective effect on cardiotoxicity caused by anthracycline chemotherapy,maintaining left ventricular ejection fraction and ventricular diameter,controlling the level of myocardial injury markers,and alleviating cardiac injury.
1 Curigliano G,Cardinale D,Dent S,et al.Cardiotoxicity of anticancer treatments:Epidemiology,detection,and management[J].CA Cancer J Clin,2016,66(4):309-325.
2 Ewer MS,Ewer SM.Cardiotoxicity of anticancer treatments[J].Nat Rev Cardiol,2015,12(9):547-558.
3 Zheng PP,Li J,Kros JM.Breakthroughs in modern cancer therapy and elusive cardiotoxicity:Critical research-practice gaps,challenges,and insights[J].Med Res Rev,2018,38(1):325-376.
4 Herrmann J.Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia[J].Nat Rev Cardiol,2020,17(8):474-502.
5 Lenneman CG,Sawyer DB.Cardio-oncology:An update on cardiotoxicity of cancer-related treatment[J].Circ Res,2016,118(6):1008-1020.
6 Cardinale D,Colombo A,Bacchiani G,et al.Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J].Circulation,2015,131(22):1981-1988.
7 Narezkina A,Nasim K.Anthracycline cardiotoxicity[J].Circ Heart Fail,12(3):e005910.
8 McGowan JV,Chung R,Maulik A,et al.Anthracycline chemotherapy and cardiotoxicity[J].Cardio vasc Drugs Ther,2017,31(1):63-75.
9 Ahl R,Matthiessen P,Fang X,et al.β-Blockade in rectal cancer surgery:A simple measure of improving outcomes[J].Ann Surg,271(1):140-146.
10 Hicks BM,Filion KB,Yin H,et al.Angiotensin converting enzyme inhibitors and risk of lung cancer:Population based cohort study[J].BMJ,363:k4209.
11 Hiebert BM,Janzen BW,Sanjanwala RM,et al.Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure:A pharmacoepidemiological study[J].Br J Clin Pharmacol,2021,87(4):1801-1813.
12王瑞芹,解英,赵素珍.生脉注射液防治阿霉素相关性心脏毒性的临床观察[J].中西医结合心脑血管病杂志,2006,4(12):1092-1093.
13蒋太生.益心解毒合剂防治阿霉素心脏毒性的研究[J].现代中西医结合杂志,2007,16(19):2645-2646.
14宁亚利,姚淑莲,李东辉,等.参芪扶正注射液对表阿霉素心脏毒性保护作用的临床研究[J].陕西中医,2008,29(2):159-161.
15顾晓怡,姜藻,董丽钧.参芪扶正液抗蒽环类化疗药物所致心脏毒性的作用[J].东南大学学报(医学版),2008,27(5):375-377.
16张勇,武海明,马华.生脉注射液对乳腺癌表阿霉素多程化疗心脏毒性的作用研究[J].中西医结合心脑血管病杂志,2009,7(9):1030-1031.
17陈贝贝.注射用益气复脉(冻干)防治蒽环类药物心脏毒性的临床研究[D].山东中医药大学,2016.
18杨邵瑜,陈雪琴,潘月龙,等等.参附注射液防治表柔比星心肌毒性疗效观察[J].中国中医急症,2010,19(8):1317-1318.
19沈娜.参附注射液防治蒽环类药物心脏毒性临床观察[J].中国中医急症,2010,19(7):1132-1133.
20庄海峰,张宇,蔡皎皓,等.右丙亚胺联合参麦注射液降低蒽环类药物心脏毒性的临床研究[J].中国肿瘤临床,2012,39(6):348-351.
21王庆月.芪扶正注射液预防蒽环类药物相关心脏毒性反应30例临床观察[J].中国医药指南,2012,10(15):273-274.
22孔嘉欣,苏旭春,闫冰川,等.黄芪多糖注射液防治蒽环类药物心脏毒性临床观察[J].新中医,2013,45(7):109-111.
23刘琦,张新峰,程旭锋,等.参麦注射液防治女性乳腺癌FAC方案心脏毒性临床研究[J].中医学报,2014,29(8):1090-1091,1094.
24刘宏杰,束家和,钟薏,等.华蟾素注射液减轻表柔比星心脏毒性的临床研究[J].中西医结合心脑血管病杂志,2014,12(6):761-762.
25刘伟,段昕波,徐鑫.心脉隆注射液对蒽环类药物所致心脏毒性的预防效果研究[J].中国全科医学,2014,17(29):3461-3464
26陈大可,王娟.生脉注射液联合左卡尼汀对阿霉素化疗患者的心肌保护作用[J].实用癌症杂志,2014,29(3):349-351.
27张明星.四逆汤防治乳腺癌蒽环类化疗药急性心脏毒性的临床研究[D].广州中医药大学,2014.
28齐泽华,韩涛,刘兆喆,等.加味当归养心汤对乳腺癌术后应用蒽环类药物的心脏毒性的影响[J].创伤与急危重病医学,2015,3(3):174-176.
29王凡.炙甘草汤预防蒽环类药物化疗所致心脏毒性的临床研究[D].石河子大学,2015.
30周祺,王瑞华.强心冲剂防治表柔比星联合化疗所致心脏毒性的临床观察[J].云南中医中药杂志,2016,37(11):40-41.
31王凡,巩平.炙甘草汤预防蒽环类药物心脏毒性的临床观察[J].现代肿瘤医学,2016,24(16):2610-2614.
32张新峰,乔翠霞,程旭锋,等.生脉散加味对乳腺癌接受含蒽环类药物化疗患者的心脏保护作用[J].辽宁中医杂志,2016,43(11):2307-2310.
33黄新宇.生脉散合桂枝甘草汤联合厄贝沙坦对阿霉素心肌损伤的保护作用观察[J].浙江中医杂志,2016,51(5):377.
34姚铁柱,徐志宏,马景涛,等.心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J].中国实验方剂学杂志,2016,22(6):154-158.
35孔嘉欣,苏旭春,戴诗蕾,等.黄芪多糖防治蒽环类药物心脏毒性的临床观察[J].中国医药导报,2017,14(20):136-139.
36郭连英,王菊美,安菊岩,等.炙甘草汤联合含阿霉素新辅助化疗方案治疗乳腺癌疗效及对心脏功能的影响[J].现代中西医结合杂志,2017,26(35):3915-3917.
37孙亚华,徐红双,张延勇.自拟参麦养心汤联合磷酸肌酸对接受CAF化疗方案的乳腺癌患者氧自由基及心脏功能的影响[J].现代中西医结合杂志,2017,26(23):2528-2531.
38解晓青,姜毅.益气保心汤减轻乳腺癌化疗后心脏毒性的临床研究[J].世界中西医结合杂志,2018,13(10):1396-1398,1422.
39付朝红,孔天东,陈露,等.益气活血养心方对乳腺癌患者蒽环类药物心脏损伤的预防作用[J].中医学报,2018,33(9):1619-1622.
40许贵勤,许言,胡少锋,等.稳心颗粒对乳腺癌术后蒽环类药物化疗时的心脏保护作用[J].南昌大学学报(医学版),2018,58(2):57-59,63.
41申兴勇,袁平.加减炙甘草汤对乳腺癌化疗致心脏毒性的临床观察及对心功能的保护作用分析[J].癌症进展,2018,16(1):106-109.
42吴启辉,张四喜,张永凯,等.心脉隆注射液对蒽环类药物致肿瘤患者心脏毒性作用的影响[J].解放军医药杂志,2018,30(9):24-27.
43唐众.心脉隆注射液用于行序贯化疗气虚血瘀证乳腺癌患者疗效及对cTnI、H-FABP的影响[J].现代中西医结合杂志,2018,27(26):2885-2888.
44杨淑莲,王茂生,郎立新,等.心脉隆注射液预防急性白血病柔红霉素化疗心脏毒性的临床研究[J].中西医结合心脑血管病杂志,2019,17(20):3190-3194.
45龙惠东,林云恩,梁仕香,等.通脉四逆汤加减对乳腺癌患者化疗后早期心肌损伤的临床观察[J].中国医学创新,2019,16(25):126-130.
46林素真.炙甘草汤改善乳腺癌蒽环类化疗致心肌毒性临床分析及机制探究分析[J].中外医疗,2019,38(25):173-175.
47王瑞华,李艳芬,邹爱英,等.黄连阿胶汤防治蒽环类化疗药物诱发心肌损伤的临床疗效及机制[J].中国实验方剂学杂志,2019,2 5(8):20-2 7.
48任建林,武帅,贾红燕.右丙亚胺联合稳心颗粒降低蒽环类药物致乳腺癌病人心脏毒性的临床疗效[J].中西医结合心脑血管病杂志,2020,18(16):2747-2749.
49 Henriksen PA.Anthracycline cardiotoxicity:An update on mechanisms,monitoring and prevention[J].Heart,2018,104(12):971-977.
50 Sala V,Della Sala A,Hirsch E,et al.Signaling pathways underlying anthracycline cardiotoxicity[J].Antioxid Redox Signal,2020,32(15):1098-1114.
51 Sobczuk P,Czerwinska M,Kleibert M,et al.Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications[J].Heart Fail Rev,2022,27(1):295-319.
52 Zhang Y,Zhang L,Zhang Y,et al.YiQiFuMai powder injection attenuates coronary artery Ligation-Induced heart failure through improving mitochondrial function via regulating ROS generation and CaMKⅡsignaling pathways[J].Front Pharmacol,2019,10:381.
53 Yang Y,Tian Y,Hu S,et al.Extract of Sheng-Mai-San ameliorates myocardial ischemia-induced heart failure by modulating Ca~(2+)-Calcineurin-Mediated Drpl signaling pathways[J].Int J Mol Sci,2017,18(9):1825.
54 Zhang GQ,Wang H,Liu WT,et al.Long-term treatment with a Chinese herbal formula,Sheng-Mai-San,improves cardiac contractile function in aged rats:The role of Ca~(2+)homeostasis[J].Rejuvenation Res,2008,11(6):991-1000.
55 Wang N,Minatoguchi S,Uno Y,et al.Treatment with sheng-mai-san reduces myocardial infarct size through activation of protein kinase C and opening of mitochondrial KATP channel[J].Am J Chin Med,2001,29(2):367-375.
56 Li J,Li Y,Zhang Y,et al.The inhibitory effect of WenxinKeli on H9C2 cardiomyocytes hypertrophy induced by angiotensinⅡthrough regulating autophagy activity[J].Oxid Med Cell Longev,2017,2017:7042872.
57 Yang X,Liu N,Li X,et al.A review on the effect of traditional Chinese medicine against anthracycline-induced cardiac toxicity[J].Front Pharmacol,2018,9:444.
58郑颂华,吴泰相,商洪才,等.中药复方临床随机对照试验报告规范2017——CONSORT声明的扩展、说明与详述[J].中西医结合心脑血管病杂志,2019,17(1):1-14.
基本信息:
DOI：10.13210/j.cnki.jhmu.20210204.002
中图分类号:R273
引用信息:
[1]刘璨,邢雁伟,苏鑫,等.中医药对肿瘤蒽环类化疗导致心脏毒性保护作用的meta分析[J].海南医学院学报,2022,28(05):377-389.DOI:10.13210/j.cnki.jhmu.20210204.002.
基金信息:
国家重点研发计划资助（2018YFC1704901）~~
2021-02-04
2021-02-04
2021-02-04